BillionToOne (BLLN) opened Q1 2026 with revenue of $108.4 million and Basic EPS of $0.39, putting fresh numbers on the table for investors tracking its recent move into profitability. The company reported quarterly revenue of $59.0 million in Q1 2025 and $108.4 million in Q1 2026, while Basic EPS moved from a loss of $0.39 to a profit of $0.39 over the same period. This sets up a clear contrast in how the income statement now converts sales into earnings. Overall, margins appear firmer and the earnings mix looks cleaner, which puts more focus on how sustainable this profitability profile is.

See our full analysis for BillionToOne.

With the headlines set by these Q1 numbers, the next step is to see how they line up with the prevailing narratives around BillionToOne's growth, risks, and profitability profile.

TTM EPS crosses US$1.00 as profits stabilize

• On a trailing twelve month basis, Basic EPS moved to US$1.00 with net income of US$24.9 million on US$354.5 million of revenue, compared with a TTM loss of US$41.6 million on US$152.6 million of revenue six quarters earlier.
• What stands out for the bullish narrative is how this shift to profitability lines up with the view that earnings can keep growing, as the latest four quarters now show net income consistently in positive territory while earlier periods carried losses.
  • Supporters of the bullish view point to this move into the black over the last year as evidence that the business model is starting to scale in both prenatal and oncology testing, even though recent reported earnings also include a one off loss of US$9.7 million that affects the quality of the TTM figures.
  • At the same time, the jump from a quarterly loss of US$4.0 million in Q1 2025 to a profit of US$18.0 million in Q1 2026 is a large step change that bulls see as consistent with their expectation of stronger future earnings, while more cautious investors may want to see how repeatable this level of profitability is.

Bulls argue that this turn to consistent TTM profitability is the key hinge for their longer term story, and the full bull case sets out how far they think that can go 🐂 BillionToOne Bull Case.

Q1 net income jumps to US$18 million

• Quarterly net income excluding extra items reached US$18.0 million in Q1 2026 on revenue of US$108.4 million, compared with US$2.5 million on US$96.1 million of revenue in Q4 2025 and a loss of US$4.0 million on US$59.0 million of revenue in Q1 2025.
• Cautious investors highlight this rapid swing as a reason to stress test the bearish narrative, because both bulls and bears agree that margins need to hold up as spending on EMR integrations such as Epic Aura, clinical studies and oncology expansion continues.
  • Bears focus on the risk that higher costs for EMR rollouts and larger oncology and MRD trials could eat into this US$18.0 million quarterly profit if revenue growth slows, especially after a period where oncology tests are described as carrying lower gross margins than prenatal.
  • What challenges the more pessimistic angle is that every quarter in 2025 after Q1 remained profitable on a net income basis, even while the company invested in integration and reimbursement efforts, which suggests current spending levels have so far been absorbed by the income statement.

Skeptics warn that this US$18 million profit could be hard to maintain if costs ramp faster than test volumes, and the bear case lays out where they see pressure building 🐻 BillionToOne Bear Case.

High sales multiple versus DCF and forecasts

• The stock trades at US$92.90 with a P/S of 12.1x against a US Healthcare industry average of 1.2x and peer average of 2.7x, while the stated DCF fair value is US$146.07 and forecasts call for earnings growth of about 62.5% per year alongside revenue growth of about 19.3% per year.
• Analysts who lean bullish argue that the combination of forecast growth and a DCF fair value above the current price supports their case, yet the same data also highlights valuation tension that more cautious investors point to.
  • On one side, the share price sitting below the DCF fair value of US$146.07 is cited as evidence that the market price does not fully reflect expected future cash flows, especially after the company shifted to trailing twelve month profitability with US$24.9 million of net income.
  • On the other side, the 12.1x P/S versus 1.2x for the wider US Healthcare group and 2.7x for peers shows that the market already prices in strong growth, so any slowdown from the roughly 19.3% revenue growth forecast or any repeat of large one off items like the US$9.7 million loss could weigh on how comfortable investors feel with that multiple.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for BillionToOne on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of optimism and concern feels familiar, it is because the story clearly has two sides. Consider acting promptly, review the underlying figures yourself, and weigh up the 3 key rewards and 2 important warning signs

See What Else Is Out There

The earnings story comes with tension, as a 12.1x P/S against much lower industry and peer averages leaves little room for softer margins or one off hits.

If that rich valuation and sensitivity to profitability worries you, consider balancing your watchlist with companies in the 51 high quality undervalued stocks that may offer more leeway on price and fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.